Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19
Background. The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, originated in Wuhan, China, has claimed millions of lives around the world. In this regard, the search for effective drugs, including the repurposing of existing ones, has become an urgent task. A promising treatment strategy a...
Saved in:
| Main Authors: | S. Ya. Loginova, V. N. Schukina, S. V. Savenko, V. V. Rubtsov, S. V. Borisevich, D. L. Chizhov, G. L. Rusinov, E. V. Verbitskiy, V. N. Charushin, S. K. Kotovskaya, V. L. Rusinov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2024-06-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/1121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antiviral Activity of Kagocel<sup>®</sup> in vitro Against Virus SARS-CoV-2
by: S. Ya. Loginova, et al.
Published: (2020-06-01) -
STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
by: L. A. Balykova, et al.
Published: (2021-12-01) -
Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01) -
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
by: Abdullah Sayiner, et al.
Published: (2022-03-01) -
EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
by: L. A. Balykova, et al.
Published: (2022-03-01)